Related references
Note: Only part of the references are listed.Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes (vol 10, 7073, 2020)
Solene De Talhouet et al.
SCIENTIFIC REPORTS (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
A systematic review of the international prevalence of BRCA mutation in breast cancer
Nigel Armstrong et al.
CLINICAL EPIDEMIOLOGY (2019)
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
Mark Robson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Ellen R. Copson et al.
LANCET ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study
Hildegunn Hoberg-Vetti et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2016)
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis
Rong Bu et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
Mohammed Aleskandarany et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
The PRECIS-2 tool: designing trials that are fit for purpose
Kirsty Loudon et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
The PRECIS-2 tool: designing trials that are fit for purpose
Kirsty Loudon et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru
J. Abugattas et al.
CLINICAL GENETICS (2015)
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia
Amanda B. Spurdle et al.
BREAST CANCER RESEARCH (2014)
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellin, Colombia
Julian Esteban Londono Hernandez et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2014)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Nasim Mavaddat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
Antonis C. Antoniou et al.
BREAST CANCER RESEARCH (2012)
Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Mieke Kriege et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improving the reporting of pragmatic trials: an extension of the CONSORT statement
Merrick Zwarenstein et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil
Magda C. B. Gomes et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Share Paper
